Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal

Acta Ophthalmologica Scandinavica

Volumn 81, Issue 1, 2003, Pages 41-46

  Fledelius, Hans C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Computerized static perimetry; Epilepsy; Goldmann kinetic perimetry; Vigabatrin; Visual field defects, reversibility; Visual field screening

Indexed keywords

VIGABATRIN;

ADOLESCENT; ADULT; AGED; ANAMNESIS; ARTICLE; CLINICAL ARTICLE; COMPUTER SYSTEM; CONTROLLED STUDY; DENMARK; DOSE RESPONSE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; PERIMETRY; PRIORITY JOURNAL; TECHNIQUE; VISION TEST; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

EID: 0038102641     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2003.00023.x     Document Type: Article

References (21)

1. Chadwick DW, Marson T & Kadir Z (1996): Clinical administration of new anti-epileptic drugs: An overview of safety and efficacy. Epilepsia 37 (Suppl. 6): S17-S22.
2. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A & Zackon D (1999): Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106: 1792-1798.
3. Eke T, Talbot J & Lawden MC (1997): Severe persistent visual field constriction associated with vigabatrin. BMJ 314: 180-181.
4. Gloor B (1993): Untersuchung mit der Goldmann Perimeter. In: Gloor B (ed). Perimetrie, Mit Besonderer Berücksichtigung der Automatischen Perimetrie. Stuttgart: Ferdinand Enke Verlag. 26-30.
5. Harding GF, Wild JM, Robertson KA, Rietbrock S & Martinez C (2000): Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology 55: 347-352.
6. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TTJM & van Veelen CWM (2000): Long-term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 84: 788-790.
7. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segars JP, Berendschot TTJM & Stilma JS (2001): Visual field loss associated with vigabatrin: Quantification and relation to dosage. Epilepsia. 42: 262-267.
8. Johnson MA, Krauss GL, Miller NR, Medura M & Paul SR (2000): Visual function loss from vigabatrin: effect of stopping the drug. Neurology 55: 40-45.
9. Kalviainen R, Nousiainen I, Mantyjärvi M et al. (1999): Vigabatrin, a gabaergic anti-epileptic drug, causes concentric visual field defects. Neurology 53: 922-926.
10. Kaykoshrov M, Goodman S, Siviter L & Nightingale S (2000): A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84: 499-504.
11. Krakow K, Polizzi G, Riordan-Eva P, Holdr G, McLeod WN & Fish DR (2000): Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9: 287-290.
12. Krauss GL, Johnson MA & Miller N (1998): Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 50: 614-618.
13. Lawden MC, Eke T, Degg C, Harding GF & Wild JM (1999): Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiat 67: 716-722.
14. Malmgren K, Ben-Menachem E & Frisén L (2001): Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 42: 609-615.
15. Manuchehri K, Goodman S, Siviter L, Nightingale S (2000): A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 84: 499-505.
16. Midelfart A, Midelfart E & Brodtkorb E (2000): Visual field defects in patients taking vigabatrin. Acta Ophthalmol Scand 78: 580-584.
17. Miller NR, Johnson MA, Paul SR et al. (1999): Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 53: 2082-2087.
18. Riise P, Fledelius HC & à Rogvi-Hansen B (2002): Vigabatrin og synsfeltdefekter. Et dansk materiale med vurdering af screening-steknikker. Ugeskr Læger. In press.
19. Sundhedsstyrelsen (1999): Vejledning om synsfeltsundersøgelse ved behandling med læge-midlet Vigabatrin. Ugeskr Læger 161: 4101-4102.
20. Uldall P, Alving J, Gram L & Høgenhaven H (1995): Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 26: 253-256.
21. Wild JM, Martinez C, Reinshagen G & Harding GF (1999): Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40: 1784-1794.